TY - JOUR
T1 - Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease
AU - Buckley, Rachel F.
AU - Maruff, Paul
AU - Ames, David
AU - Bourgeat, Pierrick
AU - Martins, Ralph N.
AU - Masters, Colin L.
AU - Rainey-Smith, Stephanie
AU - Lautenschlager, Nicola
AU - Rowe, Christopher C.
AU - Savage, Greg
AU - Villemagne, Victor L.
AU - Ellis, Kathryn A.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Introduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). Methods Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.
AB - Introduction The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). Methods Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. Results In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4–20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. Discussion High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.
KW - Amyloid
KW - PET imaging
KW - Preclinical AD
KW - Prodromal AD
KW - Subjective cognitive decline
KW - Subjective memory decline cognitively normal older adults
UR - http://www.scopus.com/inward/record.url?scp=84959212040&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2015.12.013
DO - 10.1016/j.jalz.2015.12.013
M3 - Article
C2 - 26852195
AN - SCOPUS:84959212040
SN - 1552-5260
VL - 12
SP - 796
EP - 804
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 7
ER -